Investors

H&Q Asia Pacific (H&QAP) is a leading Asian private equity firm that has managed an aggregate of over $35 billion in committed capital through 28 funds since its inception in 1985.  H&QAP is dedicated to identifying superior commercial potential in Asia and working closely with companies to unlock that untapped potential. Throughout its rich history, H&QAP has developed an extensive network specifically geared towards helping its portfolio companies emerge into global business leaders.

Formosa Laboratories, Inc. produces GMP-grade APIs and UV-filters in its modern facilities near Taipei. Formosa also provides custom synthesis service from process development to full commercial production for APIs and other specialty chemicals, with full documentation support.  In addition, Formosa has interest to invest in companies with whom they collaborate with.

China Investment & Development (CIDC), is a group that has brought together professionals from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. China Investment & Development Company, Limited has a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses.

Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in biomedical & healthcare technology investments, with emphasis on supporting the growth of early stage ventures.  We focus on unlocking hidden value across the commercialization value chain by leveraging our global network, which brings together unique expertise from industry and academia.